Stanford University
Showing 1,351-1,400 of 2,432 Results
-
Ashley Martinez, MD, MAS
Clinical Assistant Professor, Medicine - Nephrology
BioDr. Ashley Martinez is a board-certified, fellowship-trained nephrologist with the Kidney and Pancreas Transplant Program at Stanford Health Care. She is also a clinical assistant professor in the Department of Medicine, Division of Nephrology at Stanford University School of Medicine.
Dr. Martinez specializes in caring for kidney transplant recipients. She has expertise in pre-transplant evaluation and readiness, immunosuppression, kidney allograft survival, and the prevention and treatment of post-transplant complications. She prioritizes clear, personalized communication at every point to improve care.
Dr. Martinez earned her medical degree from Harvard Medical School and completed her residency in internal medicine at Massachusetts General Hospital. She completed clinical and research fellowships in nephrology at the University of California, San Francisco (UCSF), where she also earned a master’s degree in clinical research. She completed her transplant nephrology fellowship at Stanford University School of Medicine.
Dr. Martinez’s research interests focus on addressing the needs of patients impacted by language barriers. Her work has emphasized the need to improve provider-patient communication, patient education, and evaluation tools for patients with limited English proficiency. She aims to increase awareness of communication gaps and increase patient-centered communication throughout the course of kidney care.
Dr. Martinez has published her findings in peer-reviewed journals including JAMA Network Open and Kidney360. She has also presented at the National Kidney Foundation Spring Clinical Meetings.
Dr. Martinez is a member of the American Society of Nephrology, the American Society of Transplantation, and the National Kidney Foundation. -
Maya Mathur
Associate Professor (Research) of Pediatrics, of Medicine (Computational Medicine) and, by courtesy, of Epidemiology and Population Health
On Partial Leave from 2026-08-27 To 2027-03-10Current Research and Scholarly InterestsSynthesizing evidence across studies while accounting for biases
-
Michael V. McConnell, MD, MSEE
Current Research and Scholarly InterestsMy imaging research has involved clinical and molecular Imaging of cardiovascular disease, with a focus on coronary and vascular diseases, including atherosclerosis, aortic aneurysms, and vascular inflammation.
My prevention research has involved innovative technologies to reduce coronary and vascular disease, including early disease detection plus leveraging mobile health and AI to enhance heart heart in patients and populations. -
Riley McDanal
Postdoctoral Scholar, SCRDP/ Heart Disease Prevention
BioI study scalable interventions, well-being among LGBTQ+ populations, and health disparities.
-
Valerie McDonald, MD, PhD
Affiliate, Department Professorship Funds
Resident in MedicineBioValerie McDonald received her MD degree from the University of Washington. During medical school, she conducted research exploring the relationship between physical activity and healthcare utilization. She is currently a resident physician in Internal Medicine at Stanford Health Care. Her career interests include cardiovascular prevention, cardio-kidney-metabolic health, implementation science, and leveraging AI and digital health innovations to improve patient care.
Prior to medical school, Valerie earned her PhD in environmental engineering at Michigan Technology University, studying sustainable wastewater treatment. She went on to a post-doc fellowship at the Yale Center for Biospheric Studies and Center for Green Chemistry, studying sustainability in stormwater management. She worked as a Professional Engineer for 10 years, consulting on water supply and water quality improvement projects for cities and counties throughout the Western US. -
Tracey McLaughlin
Professor of Medicine (Endocrinology)
Current Research and Scholarly InterestsDr. McLaughlin conducts clinical research related to obesity, insulin resistance, diabetes, and cardiovascular disease (CVD). Current studies include: 1) the impact of macronutrient composition on metabolism, DM2 and CVD; 2) comparison of different weight loss diets on metabolism and CVD risk reduction ; 3) role of adipocytes and adipose tissue immune cells in modulating insulin resistance; 4) use of continuous glucose monitoring and multi-omics to define metabolic phenotype and precision diets
-
Erin R. McNeely, MD, FACP
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Erin McNeely is a board-certified internal medicine physician with Stanford Health Care. She is also a clinical assistant professor in the Department of Medicine, Division of Primary Care and Population Health at Stanford University School of Medicine.
Dr. McNeely specializes in disease prevention, diagnosis, and management, with a special focus on cardiovascular health, including high blood pressure and metabolic disease. She also has extensive experience in integrative medicine. Dr. McNeely believes in working with the whole person to develop individualized care plans and to meet patients’ unique health goals.
Dr. McNeely’s research interests include health equity and primary care-based value and quality improvement.
Dr. McNeely has published her research in several peer-reviewed journals, including The Journal of Heart and Lung Transplantation, Alzheimer’s & Dementia: Translational Research & Clinical Interventions, and Spatial and Spatio-Temporal Epidemiology.
Dr. McNeely is a fellow of the American College of Physicians. -
Natalia Medvedeva
Clinical Assistant Professor, Medicine - Infectious Diseases
BioDr Natalia Medvedeva specializes in the treatment of infectious diseases. She has a special interest in antimicrobial stewardship and medical education.
-
Eric Meffre
Professor of Medicine (Immunology and Rheumatology)
BioDr. Meffre obtained his PhD in Immunology from the Université d’Aix-Marseille in France before he moved to the USA as a postdoc fellow in the laboratory of Dr. Michel Nussenzweig at The Rockefeller University in New York City. He became an assistant professor at Cornell University in 2003 before being recruited at Yale University as associate professor in 2009. He was tenured at Yale in 2014 before he joined the Department of Medicine/Division of Immunology and Rheumatology at Stanford University as a tenured full professor in 2022.
Dr. Meffre’s work focuses on the etiology of autoimmune syndromes and the roles played by B cells in these diseases. His group characterized the abnormal selection of developing autoreactive B cells in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), multiple sclerosis (MS) and Sjögren’s syndrome, resulting in large numbers of autoreactive naïve B cells accumulating in the patient’s blood. Hence, these autoreactive B cells may present self-antigens to T cells and initiate autoimmune diseases. These early B cell tolerance defects are likely primary to these autoimmune diseases and may result from genetic factors such as the 1858T PTPN22 allele that segregates with RA, SLE and T1D and correlate with an impaired removal of developing autoreactive B cells.
His research goals also consist in characterizing the molecules and pathways involved in the establishment of B cell tolerance and the removal of developing autoreactive B cells generated by random V(D)J recombination through the investigation of rare patients with primary immunodeficiency (PID) enrolled through an international network. Alteration of B cell receptor (BCR) or Toll-like receptor (TLR) signaling in PID patients results in a defective central B cell tolerance and a failure to counterselect developing autoreactive B cells in the bone marrow. In contrast, functional and suppressive regulatory T cells play a key role in preventing the accumulation of autoreactive clones in the mature naïve B cell compartment. The recent development of humanized mouse models recapitulating early B cell tolerance checkpoints and their defects in autoimmune settings allow further in-depth investigation of tolerance mechanisms and the development of novel approaches to restore defective central and peripheral B cell tolerance checkpoints and thwart autoimmunity. -
Jessica Lee Mega
Affiliate, Medicine - Med/Cardiovascular Medicine
BioJessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily and former Chief Medical Officer of Google Life Sciences. She is on the Board of Directors at Boston Scientific, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy. She is a Senior Advisor at SandboxAQ and the Chair of the Investment Committee of the American Heart Association’s GRFW Venture Fund.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies and new medical technologies. She directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative and the Board of Directors at Danaher Corporation.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association and the American College of Cardiology. -
Arnav Mehta, MD, PhD
Adjunct Clinical Assistant Professor, Medicine - Oncology
BioDr. Mehta is a board-certified, fellowship-trained medical oncologist at the Stanford Medicine Cancer Center. He is also an adjunct clinical assistant professor in the gastrointestinal (GI) oncology group of the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Mehta specializes in gastrointestinal cancer, with a particular focus on pancreatic and gastric cancers. He also treats colorectal cancers. His treatment specialties include immunotherapy — helping a patient’s immune system fight cancer — and targeted therapies, which send cancer-fighting drugs to specific cancer cell molecules.
His research interests include understanding why GI cancers resist treatments and identifying new ways to treat these tumors. In particular, he is interested in GI tumor immunology, which focuses on directing a person’s immune system to help destroy cancer cells. He also has a special interest in tumor plasticity, which represents the ability of a tumor cell to evolve and develop resistance to therapies.
Dr. Mehta has earned research awards and grants from organizations including the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), and the National Institutes of Health.
Dr. Mehta has published in many peer-reviewed journals, including Nature, Nature Genetics, Nature Immunology, Nature Medicine, Nature Cancer, Cancer Discovery and Immunity. He has written book chapters on subjects including esophageal and gastric cancer. He has also presented his research on topics including tumor immunology and pancreatic cancer at dozens of symposia and meetings around the country.
Dr. Mehta is a member of the AACR and ASCO. -
Mark Mercola
Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology
BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq. -
Dr Tom Meredith, MD, PhD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr Tom Meredith, born and raised in Melbourne, Australia, is an academic interventional cardiologist and a clinical assistant professor at Stanford. He completed his medical and cardiology specialty training through the University of New South Wales and St Vincent's Hospital in Sydney, Australia. After obtaining Fellowship at the Royal Australian College of Physicians, he completed three years of coronary and structural interventional training across St Vincent’s Hospital and Stanford. Alongside his clinical training, he completed a master's degree in clinical trials research as well as a PhD through the Victor Chang Cardiac Research Institute, supported by competitive scholarship funding from the CSANZ and the Australian National Heart Foundation. During his PhD he developed and patented a novel algorithm to predict aortic stenosis severity from single-view echocardiography and his thesis was ultimately nominated for the Dean's Award. His research interests include cardiac remodelling in valvular heart disease and the application of supervised machine-learning methods to predict post-procedural outcomes. Outside medicine, Tom is a dedicated father and avid triathlete who has competed in multiple Ironman 70.3 World Championships.
-
Thomas Charles Merigan M.D.
George E. and Lucy Becker Professor of Medicine, Emeritus
Current Research and Scholarly InterestsI am now emeritus and only participate in university activities through advising my former trainees who have joined the faculty.
-
Matthew Mesias
Clinical Associate Professor, Medicine - Primary Care and Population Health
BioMatthew Mesias, M.D., is a Geriatrician and Clinical Associate Professor of Medicine at Stanford University School of Medicine. He completed his medical degree at Johns Hopkins University School of Medicine and furthered his training internal medicine residency and geriatrics fellowship at the University of Washington. He serves as the Medical Director of the Inpatient Geriatrics Consult Service at Stanford University Hospital. His academic interests include quality improvement in geriatric care, mentorship of medical trainees, and the development of curricula for geriatrics medical education. In 2023, he was awarded the HRSA Geriatric Academic Career Award, which supports his leadership and professional development while creating geriatric educational programs for community-partnered clinics.
